Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
F-star Therapeutics, Inc. FSTX
$7.12
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
156511128.00000000
-
week52high
7.12
-
week52low
2.07
-
Revenue
21167000
-
P/E TTM
-3
-
Beta
-0.34901800
-
EPS
-1.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 15 июл 2022 г. |
| SVB Leerink | Market Perform | Outperform | 24 июн 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| HC Wainwright & Co. | Buy | 17 мар 2022 г. | |
| SVB Leerink | Outperform | Outperform | 17 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Race Geoffrey | D | 3937 | 3937 | 29 июл 2022 г. |
| Race Geoffrey | D | 3937 | 3937 | 29 июл 2022 г. |
| Forster Eliot | D | 0 | 228375 | 29 июл 2022 г. |
| Forster Eliot | A | 421537 | 260977 | 29 июл 2022 г. |
| Brewis Neil | D | 0 | 70312 | 29 июл 2022 г. |
| Brewis Neil | A | 114463 | 76619 | 29 июл 2022 г. |
| Brady Todd C | A | 20000 | 20000 | 17 июн 2022 г. |
| Race Geoffrey | A | 20000 | 20000 | 17 июн 2022 г. |
| Bermingham Nessan | A | 20000 | 20000 | 17 июн 2022 г. |
| Klein Pamela M. | A | 20000 | 20000 | 17 июн 2022 г. |
Новостная лента
F-star's Delayed Acquisition Presents A Risky Opportunity
Seeking Alpha
28 янв 2023 г. в 16:00
FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Seeking Alpha
29 июл 2022 г. в 10:15
F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.
New Strong Buy Stocks for July 15th
Zacks Investment Research
15 июл 2022 г. в 08:19
GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Zacks Investment Research
24 июн 2022 г. в 11:40
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
F-star Therapeutics Shares Are Rallying Today - Read Why
Benzinga
23 июн 2022 г. в 09:27
invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million.